Fresenius Medical Care price target raised to €56 on medium-term outlook

Following Fresenius Medical Care's Capital Markets Day, BofA Securities increased its price target to €56.00 while maintaining a Neutral rating, citing achievable mid-term targets including a mid-teen EBIT margin by 2030 and a €1 billion share buyback. Despite the positive outlook and increased FY25/26 EPS estimates, the stock fell 5% in a "sell the news" reaction, with BofA noting high expectations leading up to the event. Other firms like Bernstein SocGen Group and Truist Securities also updated their outlooks, with Bernstein citing restructuring progress and projecting double-digit earnings growth, while Truist focused on the 5008x HVHDF system rollout as a key growth driver.

Analysis

Fresenius Medical Care (FMS) recently outlined revised medium-term financial objectives at its Capital Markets Day, targeting a mid-teen EBIT margin by 2030, capital expenditures of €0.8-€1.0 billion, and a reduced leverage ratio of 2.5x-3.0x from the previous 3.0x-3.5x range. The company also announced significant capital return initiatives, including a 30-40% dividend payout policy and a €1 billion share buyback program over two years, supported by a robust 13% free cash flow yield and a 1.46 current ratio. Despite these developments, which BofA Securities deemed achievable, and BofA raising its price target on FME:GR to €56.00 (from €55.00) alongside increasing its FY25 and FY26 EPS estimates by 7% and 16% respectively due to the buyback and a new €300 million FME25+ savings program, FMS shares declined 5% in a 'sell the news' reaction. This was attributed to high expectations following a roughly 30% stock appreciation from its April trough to May peak. BofA maintained a Neutral rating, noting investor focus might shift to the absence of medium-term revenue targets. Other analysts provided mixed but generally constructive updates: Truist Securities maintained a Hold rating and a $30 price target for FMS, emphasizing the 5008x HVHDF system rollout as a key growth driver. Bernstein SocGen Group increased its price target for Fresenius Medical Care to $31.50 from $26.00, projecting consistent double-digit earnings growth for the next five years driven by restructuring progress under CEO Helen Giza, and viewing the stock as a tactical buying opportunity despite a Market Perform rating. Fresenius also guided for U.S. treatment growth exceeding 2% annually and highlighted the 5008x dialysis machine roll-out as key operational drivers supporting its long-term growth and financial stability strategy.

Key Decisions for Investors

• Investors should look beyond the immediate 'sell the news' stock reaction and evaluate Fresenius Medical Care's strengthened medium-term financial targets, including improved EBIT margin guidance, reduced leverage, and significant capital returns via a €1 billion share buyback and a 30-40% dividend payout.
• Key performance indicators to monitor closely include the execution of the FME25+ €300 million savings program, the market penetration and impact of the 5008x dialysis machine, U.S. treatment growth rates, and progress towards the stated leverage and margin targets.
• While analyst price target increases from BofA and Bernstein, alongside positive EPS revisions and a specific ticker sentiment score of 0.65, suggest underlying fundamental improvements, the prevailing Neutral/Market Perform ratings and the noted absence of explicit medium-term revenue guidance warrant a balanced approach, potentially considering accumulation during periods of weakness aligned with a long-term investment horizon.